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Aberrantly expressed proteins in tumours evoke an 
immunological response. These immunogenic proteins 
can serve as potential biomarkers for the early diagno-
sis of cancers. In this study, we performed a candidate 
marker screen on macroarrays containing 38,016 hu-
man proteins, derived from a human fetal-brain expres-
sion library, with the pools of sera from breast cancer 
patients (1 pool of benign samples, 3 pools of ductal 
carcinoma and 2 pools of lobular carcinoma) and 1 
pool of sera from healthy women. A panel of 642 sero-
reactive clones were deduced from these macroarray 
experiments which include 284 in-frame clones. Over-
representation analyses of the sero-reactive in-frame 
clones enabled the identification of the sets of genes 
over-expressed in various pathways of the functional 
categories (KEGG, Transpath, Pfam and GO). Protein 
microarrays, generated using the His-tag proteins de-
rived from the macroarray experiments, were used to 
evaluate the sera from breast cancer patients (24 malig-
nant, 16 benign) and 20 control individuals. Using the 
PAM algorithm we elucidated a panel of 50 clones 
which enabled the correct classification prediction of 
93% of the breast-nodule positive group (benign & 
malignant) sera from healthy individuals’ sera with 
100% sensitivity and 85% specificity. This was fol-
lowed by over-representation analysis of the signifi-
cant clones derived from the class prediction.  
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Evaluation of auto-antibody serum biomarkers for breast cancer screening 
and in silico analysis of sero-reactive proteins 
Introduction 
 
Within the European countries in 2008 there were an 
estimated 3.2 million new cases of cancer and 1.7 mil-
lion cancer related deaths. Out of the 1.7 million can-
cer cases, 129,000 (7.5% of all forms of cancer) were 
cases of breast cancer (Ferlay et al. 2010). As a result, 
there is a great anticipation to identify novel bio-
markers for diagnosing breast cancer. 
 An immunological response can be evoked by a 
mutated or an aberrantly expressed protein resulting in 
the production of auto-antibodies. In the context of 
cancer, these immunogenic proteins are known as tu-
mour-associated antigens (TAA). The corresponding 
tumour auto-antibodies could be used as biomarkers 
for early diagnosis and prognosis of cancer (Anderson 
& LaBaer 2005, Casiano et al. 2006, Sanchez-Carbayo 
2006). Proteins like ANXA11, p53, HIP1 and ECPKA 
are known to serve as TAA biomarkers for various 
cancers (Bradley et al. 2005, Fernandez-Madrid et al. 
2004, Nesterova et al. 2006, Soussi 2000). Tomaino et 
al. (2007) used Western blot analysis to identify auto-
antibodies against pancreatic ductal adenocarcinoma 
(PDAC) associated antigens from the PDAC sera.  In 
addition, various studies have elucidated a range of 
TAAs in breast cancer, such as MUC1, HSP90, HER2/
neu, c-myc, NY-ESO-1/LAGE-1 and Lipophilin B 
(Carter et al. 2003, Chapman et al. 2007, Conroy et al. 
1995, Disis et al. 1994). However, it has been shown 
that measurement of a single TAA is neither sensitive 
nor specific enough to be used as a diagnostic bio-
marker. Assessment of auto-antibodies to a tailor-made 
panel of TAAs may have a promising diagnostic po-
tential (Piura & Piura 2011). Various studies have re-
Abstract 
Journal of Molecular Biochemistry (2012) 1, 116-128 © The Author(s) 2012. Published by Lorem Ipsum Press. 
ported panels of TAAs which differentiated the breast 
cancer patients from healthy controls with higher 
specificity but low sensitivity (Table 1). 
 For TAA profiling both macro- and microar-
rays are used. Macroarrays, blotted onto polyvi-
nylidene fluoride (PVFD) membranes, are spotted with 
E. coli clones expressing recombinant proteins. Using 
macroarrays (with the hEx1 library), Ludwig et al. 
(2009) could differentiate glioma sera from healthy 
controls with a specificity and sensitivity of 90.3% and 
87.3%, respectively. On the other hand, microarrays 
are spotted with purified recombinant proteins. Babel 
et al. (Babel et al. 2009), used protein microarrays, 
containing 8000 human GST-tagged proteins, to differ-
entiate sera from 20 colorectal cancer (CRC) patients 
and healthy individuals. They reported that antibodies 
against PIM1, MAPKAPK3, STK4, SRC, and FGFR4 
were found in high abundance in cancer samples and 
antibodies against ACVR2B were present in abun-
dance in healthy controls (Babel et al. 2009). 
 In this article we describe the identification of 
a panel of 642 sero-reactive clones from a collection of 
38,016 recombinant protein expressing clones (hEx1 
library (Büssow et al. 2000)) using macroarrays and 
sera from breast cancer patients and healthy controls. 
After identification of the panel of sero-reactive clones 
we used the “GeneTrail” gene set analysis toolkit to 
find the genes which are significantly over-represented 
and are accumulated into certain functional categories 
(Transpath, Pfam and GO). GeneTrail is an efficient 
software tool which enables a statistical evaluation of 
high-throughput genomic or proteomic data sets with 
regards to the enrichment of functional categories. Fur-
thermore, the genes expressed by the 642 sero-reactive 
clones were compared to the SEREX (serological ex-
pression of cDNA expression libraries) database and 
their role in cancer is discussed. Using the recombinant 
proteins derived from the 642 sero-reactive clones, 
protein microarrays were generated which enabled dis-
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TAA/panel 
of TAA 
Sensitivity 
(%) 
Specificity 
(%) 
Study size 
Ages (Mean average in 
years) 
Method used Ref. 
ASB-9 
SERAC1 
RELT 
80 
100 
  
87 patients & 
87 controls 
n.a 
cDNA T7 
phage library 
protein screen-
ing  with 
ELISA 
(Zhong et al. 
2008) 
p16 
p53 
c-myc 
43.9 97.6 
41 patients & 
82 controls 
n.a ELISA 
(Looi et al. 
2006, Zhong 
et al. 2008) 
PPIA 
PRDX2 
FKBP52 
MUC1 
HSP60 
73 85 
60 primary 
breast cancer 
patients, 82 
carcinoma in 
situ patients & 
93 controls 
  
55 (Patients) 
ELISA 
(Desmetz et 
al. 2009) 
p53 
c-myc 
HER2 
NY-ESO-1 
BRCA2 
MUC1 
64 85 
97 patients  & 
94 controls 
59
(Patients) 
54
(Controls) 
ELISA 
(Chapman et 
al. 2007) 
IMP1 
p62 
Koc 
p53 
c-MYC 
cyclin B1 
survivin 
70 95 
64  Chinese 
patients, 82 
healthy Chinese 
controls & 264 
healthy USA 
controls 
n.a ELISA 
(Koziol et 
al. 2003, 
Zhang et al. 
2003) 
Table 1. TAA panels identified in breast cancer patients reported in various studies. 
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Pool 1 Pool 2 Pool 3 Pool 4 Pool 5 Pool 6 Pool 7 Control Benign Malignant 
Number of samples 10 10 10 10 10 10 10 20 16 24 
Median age (years) 43 73 71 57.5 65.5 54 63 77 45
a 60 
Gradingb   
G1     5     3       6 
G2     5 10   7 9     11 
G3         10   1     5 
P53 Positive     1 1 9 2 1       
Hormone receptor 
positive 
  
Her2/neu       2 3   2     8 
Estrogen     10 10 1 10 10     18 
Progesterone     10 8   10 9       
pT stagec(%)   
Tx, Tis, T1; T1a, 
T1b, T1c, T1mic, T2, 
T3; T4b 
    
0; 0; 0; 
20; 30; 
40; 10; 
0; 0; 0. 
0; 10; 
0; 0; 0; 
10; 0; 
60; 0; 
10. 
0; 0; 0; 
10; 0; 
30; 10; 
40; 0; 
0. 
0; 0; 0; 
0; 20; 
50; 0; 
10; 10; 
0. 
0; 0; 0; 
0; 0; 
20; 0; 
60; 20; 
0. 
    
4.17; 4.17; 
16.67; 
29.17; 4.17; 
12.50; 0; 
4.17 
pN staged(%)   
Nx; N0; N1; N1a, 
N1biv; N1mi; N2a; 
N3 
    
0; 90; 
0; 0; 0; 
0; 0; 0. 
10; 0; 
10; 20; 
10; 0; 
30; 10 
0; 60; 
0; 0; 0; 
0; 20; 
10 
0; 90; 
0; 0; 0; 
0; 0; 0. 
0; 0; 
10; 50; 
0; 10; 
0; 0. 
    
20; 50; 10; 
10; 10 
Menopause statuse   
Pre-menopause 5   3 2 2 3 1   5 3 
Peri-menopause           1         
Post-menopause 1   7 7 7 5 9     18 
Table 2. Clinical and pathological characteristics of the sera used in macro- and microarray screenings. Pools 1-7 were used for 
the macroarray experiments. Pools 1 and 2 consist of sera from patients with benign fibroadenoma and healthy controls, respec-
tively. Pools 3-5 comprise sera from patients with ductal carcinoma while pools 6 and 7 contain sera from patients with lobular 
carcinoma. The data enlisted in the columns, Control, Benign and Malignant, are the samples used for microarray experiments. 
aData available for 14 patients. bData available for 22 malignant patients used in microarray experiments. G1 (low-grade), G2 
(intermediate grade) and G3 (high-grade). Low-grade tumours are usually slow growing and are less likely to spread. High-
grade tumours are likely to grow more quickly and are more likely to spread. cData available for 24 malignant patients used in 
microarray experiments. dData available for all patients (40 samples, Pools 3-6) and 9 samples from Pool 7; used in macroarray 
experiments and data available for 20 Malignant patients. eData available for 47 patient (Pools 3-7) and 6 benign samples (Pool 
1); used in macroarray experiments and data available for 26 patients; used in microarray experiments. 
tinguishing serum samples from breast-nodule positive 
patients (benign and malignant) and healthy controls. 
 
Materials and Methods 
 
Serum Samples 
Serum samples were obtained after approval from pa-
tients and healthy women and were stored at -80°C. 
The study was approved by the Ethics Committee of 
the Medical University of Vienna and the General 
Hospital of Vienna (study number: 143/2007). For 
macroarray experiments, an aliquot (80 µL) of each 
serum sample was used for the generation of 7 serum 
pools. For microarray experiments, 60 serum samples 
(malignant n=24; benign n=16; healthy n=20) were 
used. The pathological and clinical cohort characteris-
tics of the breast cancer samples can be found in Table 
2. 
 
Candidate marker screening 
Protein macroarrays, containing duplicates of 38,016 
clones (hEx1 library) were purchased from RZPD 
(now Source Bioscience), Germany. The protein fea-
tures were generated by expression of spotted E. coli 
clones, which harbour an expression vector, 
pQE30NST. The expressed recombinant proteins are 
His-Tagged. Duplicate clones are present on a set of 2 
macroarrays and the macroarrays were processed ac-
cording the detailed protocol for membrane processing 
which can be found on the Source Bioscience home-
page (http://www.lifesciences.sourcebioscience.com/
media/290406/sbs_ig_manual_proteinarray_v1.pdf). 
 In a pre-test, the reliability of auto-antibody 
screening on PVFD membranes containing 38,016 fe-
tal brain proteins was evaluated using the native serum 
samples and the IgG-purified serum fraction isolated 
by affinity purification of immunoglobulins. The puri-
fication of IgG from the serum was done using 
Melon™ Gel IgG Purification Kit (Thermo Scientific) 
and the procedure was followed as per the manufac-
turer’s instructions. In this pre-test, an individual se-
rum sample was tested against a pool of 10 healthy 
control serum samples (also including the single indi-
vidual sample) with and without the Melon™ Gel IgG 
Purification in order to decide whether to apply serum 
or the affinity enriched Ig-fraction onto the macroar-
rays. 
 Based on the results derived from the pre-test 
we decided to use the pools of native serum samples to 
perform a candidate marker screen on PVFD mem-
branes containing 38,016 human proteins derived from 
hEx1, a human fetal-brain expression library. In order 
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Figure 1. An overview of the number of clones and genes identified in this study.  
 
to have a measure of the reproducibility of the 
macroarrays, all the membranes were hybridized with 
a male-serum sample (with no personal or familial 
breast cancer history). The membranes were then 
stripped and blinded duplicates of each pool of patient  
(Pool 3-7) and non-malignant (Pool 1 & 2) sera were 
applied onto the macroarrays. Thereafter, data was 
generated upon signal detection according to the proto-
col from RZPD, Germany. 
 The selection of the clones was done on the 
basis of sero-reactivity in all experiments. A total of 
642 sero-reactive clones (after excluding duplicates) 
from different screening experiments were considered 
for the production of microarrays. 
 
GeneTrail analysis 
GeneTrail analysis was done for 284 in-frame clones 
among the panel of 642 sero-reactive clones. A statisti-
cal approach of Over-Representation Analysis (ORA) 
was followed for the comparison of the test set with 
the reference set (“Heidelberg human fetal brain”), 
provided by the gene set analysis tool (Backes et al. 
2007, Keller et al. 2007). The analyses were performed 
with the following parameters:  Multiple testing adjust-
ment method: false discovery rate (FDR), significance 
level threshold (α-level): 0.05. 
 
Protein microarray production and processing 
E. coli clones were cultured using the autoinduction 
protocol according to Stempfer et al. (2010). Recombi-
nant protein expression was induced by cultivation of 
E. coli clones in autoinduction medium (SB medium) 
and purified using Ni-NTA agarose (Qiagen). Elution 
of His-Tag proteins was performed using elution 
buffer (50 mM KH2PO4 and 50 mM K2HPO4,  pH 8.0, 
500 mM imidazole, 0.01% SDS and 0.01% NaN3). 
Purified His-Tag proteins were then spotted on AR-
Chip Epoxy slides (Preininger et al. 2004). Each mi-
croarray consisted of 4 sub-arrays with protein anti-
gens printed in duplicates. Clarified E. coli lysate with 
a concentration of 0.5 mg/mL was used as a positive 
control and plain buffer spots as a negative control. 
Processing of the protein microarrays was performed 
as described previously (Stempfer et al. 2010). The 
processed microarray images were captured using an 
Axon Genepix 4000A microarray scanner (Molecular 
Devices, Union City, CA). Median fluorescence inten-
sities after subtraction of local background were calcu-
lated from the scanned array images and used for the 
data analysis. 
 
Statistical analysis 
The statistical analysis of the data from the scanned 
images of macroarrays was performed using R version 
2.10.0 (R Development Core Team 2005). For mi-
croarray data analyses in addition to R, BRB-
ArrayTools Version: 3.6.0 - Stable Release (Simon & 
Lam 2009) were also used. 
 For class prediction, we used the Prediction 
Analysis for Microarrays (PAM) algorithm. The PAM 
algorithm uses the “nearest shrunken centroid” method 
which identifies a subset of significant genes/clones 
for the best classification of the samples (Tibshirani et 
al. 2002). Cross-validation of the predicted class and 
the true class was performed. 
 
Results 
 
In brief, from the collection of 38,016 cDNA expres-
sion clones 642 clones were selected based on their 
sero-reactivity. Over-representation analysis was per-
formed using 284 in-frame clones. Protein microarrays 
were generated using the purified proteins from the 
642 sero-reactive clones. Using these protein microar-
rays breast-nodule positive samples could be differen-
tiated from healthy controls. A schematic overview of 
the results obtained during the course of the study is 
shown in Figure 1. 
 
Evaluation of purified IgG versus serum for mem-
brane screening 
Clones on the membranes which were reactive to na-
tive serum samples (pooled serum samples and single 
serum sample) and purified IgG (same as above) were 
compared. Signals of duplicate spots were counted as 
positive signals within the colour-range of 0-4 based 
on the staining intensity of the spots (Figure 1S; see 
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Purified  
IgG-Single (1) 
Purified  
IgG-Pool (2) 
Native  
sera-Pool (3) 
Native  
serum-Single (4) 
Purified IgG- Single (1) 22 7 11 19 
Purified IgG- Pool (2) 7 32 21 11 
Native sera- Pool (3) 11 21 67 31 
Native serum- Single (4) 19 11 31 125 
Table 3. Number of clones with overlapping reactivity within different samples analysed.  
The numbers (1-4) in the brackets correspond to the lanes in the Figure 1S (see supplementary data). 
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supplementary data). A total of 170 sero-reactive 
clones were identified during this experiment. 32 and 
67 clones reacted positively to pooled purified IgG and 
native pooled serum samples, respectively, whereas 22 
and 125 clones were observed reacting positively to 
purified IgG and native serum sample, respectively 
(Table 3). Based on the number of clones showing a 
positive reaction, we decided to use native sera for 
membrane screening. 
 
Antigen Identification on Macroarrays 
Macroarrays were hybridized with pooled samples 
(pools 1-7) after being processed with a single serum-
control (reference) and then stripped. Hierarchical 
clustering results of the reference serum sample on 
different membranes used for sample analysis are 
shown in Figure 2S (right part; see aupplementary 
data) and the number of the sero-reactive clones from 
each membrane can be found in Table 1S (see supple-
mentary data). The correlation coefficient values de-
rived from the processed membranes with the same 
reference serum range from 0.68 to 0.98. Analysis of 
signal intensities derived from the membranes, proc-
essed with blinded duplicates (Pools 1-7) was per-
formed and sero-reactive clones were identified (left 
part of Figure 2S; see supplementary data). The corre-
lation coefficients of the two runs of each serum pool 
(Pool 1-7) on macroarrays were found to be ranging 
from 0.12 to 0.89. 
 A total of 1691 sero-reactive clones were 
found, including the clones identified from the “IgG 
versus serum” pre-test. Of all these, 642 were identi-
fied as unique clones showing sero-reactivity in all the 
macroarray experiments. 284 out of 642 clones were 
confirmed (based on their DNA sequence) to be cloned 
in-frame. Out of the 284 in-frame clones, 71 reacted 
positively to the serum samples from benign breast 
cancer patients, while 41 and 133 showed a positive 
reaction to the serum samples from health control and 
malignant breast cancer patients, respectively. 
 We decided to use all the 642 clones found 
positive within all the experiments for protein expres-
sion and thereby use the subsequent proteins for the 
production of protein microarrays. 
 
In silico analysis of sero-reactive clones 
Out of 284 in-frame clones, 181 code for unique pro-
teins. Upon comparison of the 181 genes with 1545 
genes from the SEREX database (http://www.licr.org/
D_programs/d4a1i_SEREX.php), we found 34 genes 
over-lapping between the lists. These 34 genes have 
been reported in the SEREX database from a variety of 
cancer studies. Among them, 7 genes (ALDOA, 
CENBP, EEF2, GAPDH, MAZ, PRDX1 and TP53) 
are reported in various cancer studies as TAAs (Table 
4). 
 Using GeneTrail, in silico analysis of the 284 
in-frame clone protein sequences (test set) was per-
formed to retrieve information about their functional 
categories (KEGG, Transpath, Pfam and GO) as well 
as their sub-categories, protein families, domains and 
pathways (Table 5). The number of genes annotated in 
the test set to the selected functional categories was 
found to be 168, out of 284 sequences, while the num-
ber of genes annotated in the “Heidelberg human fetal 
brain” reference set were 3527, out of 3553 sequences. 
It was found that the observed number of genes in-
volved in cellular processes and various pathways was 
higher than expected. For example, the expected num-
ber of genes involved in the sub-category “cellular 
process” was 121 while the observed number was 
found to be 139 when compared to the reference set, 
with a p-value of 0.03. This indicates the over-
representation of genes involved in the respective 
functional categories in breast cancer. Some of the sub
-categories which were enriched in the test set when 
compared to the reference set are cellular process 
(GO), wnt pathway (Transpath) and R3H domain 
(Pfam). The sum of the genes found over-represented 
in all the enriched subcategories of Transpath, Pfam 
and GO were found to be 3, 21 and 159, respectively. 
No sub-category pertaining to KEGG was found en-
riched in the test set compared to the reference set. A 
detailed list of sub-categories, the genes encoded by 
the sero-reactive clones and the number of expected 
and observed genes are shown in the Tables 2S, 3S and 
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Class Benign Malignant Normal Sensitivity Specificity PPV NPV 
Benign 2 13 1 0.125 0.932 0.4 0.745 
Malignant 2 15 7 0.625 0.556 0.484 0.69 
Normal 1 4 15 0.75 0.8 0.652 0.865 
Table 5. Prediction of classes (Benign, Malignant and Control) using the classifier from PAM algorithm. A cross-
tabulation of the classes in rows (true) versus columns (predicted) and the corresponding sensitivity, specificity, positive pre-
dictive value (PPV) and negative predictive value (NPV) is shown in the table. 
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4S (see supplementary data). 
 
Protein microarray analysis 
We used the BRB array tools to analyze the data de-
rived from the microarrays processed with patient and 
healthy control sera. Using the PAM algorithm, we 
identified 45 significant clones enabling the classifica-
tion of benign, malignant and control samples (Table 
5S; see supplementary data). Out of 16 benign breast 
cancer samples 13 were predicted as malignant and 1 
as control. Out of 24 malignant samples, 15 were cor-
rectly identified as malignant and out of 20 control 
samples, 15 were identified as healthy controls (Table 
5). 
 Since the majority of benign samples were 
identified as malignant, we decided to compare the 
breast-nodule positive samples with the healthy con-
trols. We identified 50 significant clones which en-
abled the classification of breast-nodule positive sam-
ples and healthy controls (Table 6). These clones gave 
93% correct classification prediction of breast-nodule 
positive sera from normal sera with 100% sensitivity 
and 85% specificity. 4 out of 16 control samples were 
predicted as breast-nodule positive, while all of the 40 
breast-nodule positive samples were correctly pre-
dicted (Table 7). 
 Concerning the lists derived using the PAM 
algorithm, 12 clones were found significant in both. 
The lists of significant clones were compared to the list 
of positively reacting clones to breast-nodule positive 
sera and healthy control sera. 40 clones were found to 
react positively to the breast-nodule positive sera and 9 
reacted positively to the healthy control sera, exclu-
sively. 14 clones reacted positively to sera from both 
patients and controls. 
 To find the set of genes among the 34 genes 
encoded by the 50 significant clones (that gave 93% 
correct classification prediction) which are over-
represented in the functional categories like KEGG, 
Transpath, Pfam and GO we used GeneTrail with 
“Heidelberg human fetal brain” as the reference set. 
The parameters for the analysis were identical to the 
ones previously used for the analysis of the 284 in-
frame clones. The number of genes found annotated 
within the test set of 43 genes for KEGG, Transpath, 
GO and Pfam were found to be 7, 1, 27 and 26, respec-
tively. However, no genes related to any of the KEGG, 
Transpath and GO were found to be over-represented 
in the test set when compared to the reference set. 2 
genes, ARPP21 and SPAG7 were found to be over-
represented in the R3H domain sub-category of Pfam 
(p-value of 0.001). The expected number of genes was 
0.05 while the observed number of genes was 2. 
 
Discussion 
 
Over the years, macroarrays spotted with cDNA ex-
pression clones have been used for TAA profiling. 
Macroarrays spotted with hEx1 cDNA expression li-
brary clones have been used for the identification of 
auto-antibodies from patients with glioma, chronic 
obstructive pulmonary disease (COPD) and Wilm’s 
tumour (Leidinger et al. 2009, Schmitt et al. 2011). 
Auto-antibodies are known to be present in the serum 
prior to the onset of breast, lung and prostate cancer 
(Abendstein et al. 2000, Lubin et al. 1995, Trivers et 
al. 1996). This opens up the possibility of using these 
antibodies as serological tools for the early diagnosis 
and management of cancer. 
 We used these macroarrays for identifying a 
panel of 642 sero-reactive clones from a collection of 
38,016 cDNA expression clones. An initial experiment 
was conducted to check the performance of the 
macroarrays when hybridized with purified IgG and 
native serum. We observed that the number of positive 
clones was higher when using native sera, compared to 
purified IgG. In this regard, we decided to use native 
serum samples for TAA profiling. 
 To test for reproducibility, a reference serum 
was hybridized on the macroarrays which were then 
stripped and hybridized with blinded duplicates of se-
rum pools from breast cancer patients and healthy con-
trols (Pools 1-7). Blinded duplicates of the serum pools 
were used to avoid experimental bias. Signal intensi-
ties derived from the sero-reactive clones were used 
for hierarchical clustering. Although the results from 
the single control serum analysed on every single 
membrane did cluster in a distinct tree, the sum of the 
positive clones detected from each pool in both of the 
repeated analyses did not cluster with respect to the 
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Table 7. Prediction of classes (Breast-nodule positive and Control) using the classifier from the PAM algorithm. A cross-
tabulation of the classes in rows (true) versus columns (predicted) and the corresponding sensitivity, specificity, positive pre-
dictive value (PPV) and negative predictive value (NPV) is shown. 
Class Control Breast-nodule positive Sensitivity Specificity PPV NPV 
Control 16 4 0.8 1 1 0.909 
Breast-nodule positive 0 40 1 0.85 0.93 1 
sample groups “normal”, “benign” and “5 different 
pools of ductal and lobular breast tumour” (Pools 1-7) 
(Figure 2). A total of 642 clones were found positive 
within all the macroarray experiments (including posi-
tive clones detected along the pre-test). 
 Out of the panel of 642 sero-reactive clones 
identified from the macroarray experiments, 284 
clones are cloned in-frame. 181 proteins were found to 
be encoded by the 284 clones, out of which 34 protein 
encoding genes were found to be enlisted in the 
SEREX database. These genes were reported in the 
database from various cancer studies. Through litera-
ture search we found 7 (ALDOA, CENPB, EEF2, 
GAPDH, MAZ, PRDX1 and TP53) out of 34 genes to 
be reported as TAAs against a variety of cancers 
(Table 5). In a study conducted by Suzuki et al. (2010) 
on the identification of melanoma antigens by a sero-
logical proteome approach, 5 genes (ALDOA, EEF2, 
GAPDH, ENO1 and HNRNP) showed high reactivity 
in patient sera incubated with G361 cell line protein 
spots, as compared to melanocytes. In another study 
antibodies against ALDOA were identified in the sera 
of patients with Hepatocellular carcinoma (Looi et al. 
2008). The CENPB gene has been reported to be sig-
nificantly expressed in autoimmune diseases (Nakano 
et al. 2000) and several studies have shown CENPB 
along with TP53 to be markedly associated with breast 
cancer survival and prognosis (Kulic et al. 2010). Over
-expression of the genes CENBP, MAZ and PRDX1 
was postulated to be linked to regulation of tumour 
progression, proliferation and metastasis (Liang et al. 
2004, Zaytseva et al. 2008). PRDX1 was found to be 
overexpressed in human oesophagus squamous cell 
carcinoma and MAZ protein isolated from a cerebellar 
expression library showed significant reactivity against 
sera from patients with Hodgkin’s disease (Bataller et 
al. 2003). 
 Information on the molecular mechanisms is 
important in understanding cellular behaviour and in 
predicting the reasons for dysregulation, which may 
lead to cancer (Krull et al. 2006). In silico analysis was 
performed with the aim of identifying any set of genes, 
among the genes expressed by the sero-reactive clones, 
which cluster together in accordance with certain func-
tional categories like Transpath, Pfam and GO and are 
over-represented in breast cancer. Transpath is a data-
base which provides information on signalling mole-
cules, their reactions and the pathways these molecules 
are involved in (Schacherer et al. 2001). KEGG is a 
collection of databases related to genomes, enzymatic 
pathways and biological chemicals in the cells 
(Kanehisa et al. 2004).  Pfam is a database of protein 
families based on multiple sequence alignments and 
profile hidden Markov models (Bateman et al. 2004, 
Liu et al. 2011b). GO is an initiative which helps to 
standardize the representation of genes and gene prod-
uct attributes across species and databases (The Gene 
Ontology Consortium 2000). GO provides structured 
ontologies which classify the gene products with re-
gards to biological processes, cellular components and 
molecular functions irrespective of species (Lee et al. 
2007). In a meta-analysis conducted by Chopra, global 
cancer maps for KEGG, GO and Pfam were created 
based on 23 breast cancer microarray expression data 
sets. These maps revealed “hotspots” of activation and 
de-activation of breast cancer (Chopra 2009). 
 In order to have a better understanding of the 
genes/proteins encoded by the sero-reactive clones and 
their overexpression in various pathways, we em-
ployed a web based toolkit called GeneTrail. We com-
pared the 284 in-frame clones (test set) with a refer-
ence set (“Heidelberg human fetal brain”). No genes 
were found to be over-represented in any of the KEGG 
pathways in the test. A significant over-representation 
of the genes involved in various enriched sub-
categories of Pfam, Transpath and GO was observed. 
A detailed list of over-represented genes pertaining to 
the pathways and protein families are shown in the 
supplementary data. 
 The duplicates of the macroarrays processed 
with the same serum samples identified a varying 
number of positive clones (Table 1S; see supplemen-
tary data) showing limited reproducibility. The mem-
branes were purchased and were produced so that the 
spotted cDNA expression clones are grown on the 
membranes. Recombinant protein expression is in-
duced directly on these membranes and protein immo-
bilization is performed upon lysis of the bacterial cell. 
It may be presumed that macroarrays, despite being 
derived from the same batch, present higher variability 
compared to arrays printed with formerly purified pro-
teins. Although the reproducibility of the macroarrays 
was not good enough to draw conclusions, we could 
identify a sizable panel of clones which we used for 
recombinant protein expression and purification. Pro-
tein microarrays serve as a very good alternative to 
protein macroarrays and have certain advantages. One 
of them is that the signals derived from macroarrays 
are not as dynamic as compared to the 16 bit (0-216) 
dynamic range of standard microarrays. Only a few 
microliters (approximately 10 µL) of serum sample are 
enough for the validation of auto-antibody signatures. 
In our previous experiment, we observed that the sig-
nal patterns obtained by microarray analysis of brain 
and lung tumour patients' sera were highly reproduci-
ble (R=0.92-0.96) (Stempfer et al. 2010).  
 The panel of 642 sero-reactive clones obtained 
from the macroarray screenings were used for the ex-
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pression of His-tag proteins. These recombinant pro-
teins were used for the production of targeted protein 
microarrays for TAA profiling using serum samples 
from breast cancer patients (n=24), females with be-
nign fibroadenomas (n=16) and control individuals 
(n=20). Upon statistical evaluation of the signal inten-
sities derived from the processed microarrays using the 
PAM algorithm, we could differentiate serum samples 
obtained from breast-nodule positive patients with 
100% sensitivity 85% specificity. When we tried to 
differentiate all three classes (benign, malignant and 
healthy controls), we had only 53% correct classifica-
tion prediction. Furthermore, GeneTrail analysis of the 
genes expressed by the classifier clones showed en-
richment of the R3H domain.   
 
Conclusion 
 
We used macroarrays for a broad screening and could 
deduce a panel of 642 sero-reactive clones from an 
expression library consisting of 38,016 recombinant 
protein expressing clones. In silico analysis of the in-
frame clones revealed enrichment of functional catego-
ries like Transpath, Pfam and GO in breast cancer. Us-
ing the recombinant proteins derived from 642 sero-
reactive clones we generated a targeted array for TAA 
profiling using patient sera and controls. With these 
protein microarrays, breast-nodule positive (benign 
and malignant) sera could be differentiated from 
healthy control sera using 50 clones derived from the 
PAM algorithm. 
 
Conflicts of Interest 
 
The authors declare that they have no conflicts of in-
terest. 
 
Acknowledgements 
 
We want to thank Michael Stierschneider, Agnes Burg, 
Rudolf Pichler, Silvia Schönthaler and Ronald Ku-
lovics (AIT) for their help with the E. coli cultivation, 
protein isolation and printing microarrays. Above all, 
we thank the Jubiläumsfonds der Österreichischen Na-
tional bank for funding this study (project no. 12551). 
 
References 
 
Abendstein B, Marth C, Muller-Holzner E, Widschwendter 
M, Daxenbichler G & Zeimet AG 2000 Clinical significance 
of serum and ascitic p53 autoantibodies in epithelial ovarian 
carcinoma. Cancer 88 1432-1437. 
Anderson KS & LaBaer J 2005 The sentinel within: exploit-
ing the immune system for cancer biomarkers. 
J.Proteome.Res. 4 1123-1133. 
Atalay C, Atalay G, Yilmaz KB & Altinok M 2005 The role 
of anti-CENP-B and anti-SS-B antibodies in breast cancer. 
Neoplasma 52 32-35. 
Atalay C, Dogan L & Atalay G 2010 Anti-CENP-B antibod-
ies are associated with prolonged survival in breast cancer. 
Future Oncol 6 471-477. 
Babel I, Barderas R, az-Uriarte R, Martinez-Torrecuadrada 
JL, Sanchez-Carbayo M & Casal JI 2009 Identification of 
tumor-associated autoantigens for the diagnosis of colorectal 
cancer in serum using high density protein microarrays. Mol 
Cell Proteomics 8 2382-2395. 
Backes C, Keller A, Kuentzer J, Kneissl B, Comtesse N, 
Elnakady YA, Muller R, Meese E & Lenhof HP 2007 Gene-
Trail--advanced gene set enrichment analysis. Nucleic Acids 
Res 35 W186-W192. 
Bataller L, Wade DF, Graus F, Rosenfeld MR & Dalmau J 
2003 The MAZ protein is an autoantigen of Hodgkin's dis-
ease and paraneoplastic cerebellar dysfunction. Ann Neurol 
53 123-127. 
Bateman A, Coin L, Durbin R, Finn RD, Hollich V, Grif-
fiths-Jones S, Khanna A, Marshall M, Moxon S, Sonnham-
mer EL, Studholme DJ, Yeats C & Eddy SR 2004 The Pfam 
protein families database. Nucleic Acids Res 32 D138-D141. 
Bradley SV, Oravecz-Wilson KI, Bougeard G, Mizukami I, 
Li L, Munaco AJ, Sreekumar A, Corradetti MN, Chinnaiyan 
AM, Sanda MG & Ross TS 2005 Serum antibodies to hunt-
ingtin interacting protein-1: a new blood test for prostate 
cancer. Cancer Res 65 4126-4133. 
Briasoulis E, Kamposioras K, Tzovaras V, Pafitanis G, 
Kostoula A, Mavridis A & Pavlidis N 2008 CENP-B spe-
cific anti-centromere autoantibodies heralding small-cell 
lung cancer. A case study and review of the literature. Lung 
Cancer 60 302-306. 
Büssow K, Nordhoff E, Lubbert C, Lehrach H & Walter G 
2000 A human cDNA library for high-throughput protein 
expression screening. Genomics 65 1-8. 
Carter D, Dillon DC, Reynolds LD, Retter MW, Fanger G, 
Molesh DA, Sleath PR, McNeill PD, Vedvick TS, Reed SG, 
Persing DH & Houghton RL 2003 Serum antibodies to lipo-
philin B detected in late stage breast cancer patients. Clin 
Cancer Res 9 749-754. 
Casiano CA, Mediavilla-Varela M & Tan EM 2006 Tumor-
associated antigen arrays for the serological diagnosis of 
cancer. Mol Cell Proteomics 5 1745-1759. 
Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston 
C, Sahin U, Barnes A & Robertson J 2007 Autoantibodies in 
breast cancer: their use as an aid to early diagnosis. Ann 
Oncol 18 868-873. 
Chopra P: Data Mining Techniques to Enable Large-scale 
Exploratory Analysis of Heterogeneous Scientific Data. PhD 
Thesis. North Carolina State University, Department of 
Computer Science; 2009. 
Conroy SE, Gibson SL, Brunstrom G, Isenberg D, Luqmani 
Y & Latchman DS 1995 Autoantibodies to 90 kD heat-
shock protein in sera of breast cancer patients. Lancet 345 
126. 
Dalifard I, Daver A & Larra F 1999 Cytosolic p53 protein 
and serum p53 autoantibody evaluation in breast cancer. 
Journal of Molecular Biochemistry, 2012   126 
Comparison with prognostic factors. Anticancer Res 19 
5015-5022. 
Desmetz C, Bascoul-Mollevi C, Rochaix P, Lamy PJ, 
Kramar A, Rouanet P, Maudelonde T, Mange A & Solassol 
J 2009 Identification of a new panel of serum autoantibodies 
associated with the presence of in situ carcinoma of the 
breast in younger women. Clin Cancer Res 15 4733-4741. 
Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen 
W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston 
RB & . 1994 Existent T-cell and antibody immunity to HER
-2/neu protein in patients with breast cancer. Cancer Res 54 
16-20. 
Ferlay J, Parkin DM & Steliarova-Foucher E 2010 Estimates 
of cancer incidence and mortality in Europe in 2008. Eur J 
Cancer 46 765-781. 
Fernandez-Madrid F, Tang N, Alansari H, Granda JL, Tait 
L, Amirikia KC, Moroianu M, Wang X & Karvonen RL 
2004 Autoantibodies to Annexin XI-A and Other Autoanti-
gens in the Diagnosis of Breast Cancer. Cancer Res 64 5089
-5096. 
Kanehisa M, Goto S, Kawashima S, Okuno Y & Hattori M 
2004 The KEGG resource for deciphering the genome. Nu-
cleic Acids Res 32 D277-D280. 
Keller A, Backes C & Lenhof HP 2007 Computation of sig-
nificance scores of unweighted Gene Set Enrichment Analy-
ses. BMC Bioinformatics 8 290. 
Koziol JA, Zhang JY, Casiano CA, Peng XX, Shi FD, Feng 
AC, Chan EK & Tan EM 2003 Recursive partitioning as an 
approach to selection of immune markers for tumor diagno-
sis. Clin Cancer Res 9 5120-5126. 
Krull M, Pistor S, Voss N, Kel A, Reuter I, Kronenberg D, 
Michael H, Schwarzer K, Potapov A, Choi C, Kel-
Margoulis O & Wingender E 2006 TRANSPATH: an infor-
mation resource for storing and visualizing signaling path-
ways and their pathological aberrations. Nucleic Acids Res 
34 D546-D551. 
Kulic A, Sirotkovic-Skerlev M, Jelisavac-Cosic S, Herceg 
D, Kovac Z & Vrbanec D 2010 Anti-p53 antibodies in se-
rum: relationship to tumor biology and prognosis of breast 
cancer patients. Med Oncol 27 887-893. 
Lee D, Redfern O & Orengo C 2007 Predicting protein 
function from sequence and structure. Nat Rev Mol Cell Biol 
8 995-1005. 
Leidinger P, Keller A, Heisel S, Ludwig N, Rheinheimer S, 
Klein V, Andres C, Hamacher J, Huwer H, Stephan B, 
Stehle I, Lenhof HP & Meese E 2009 Novel autoantigens 
immunogenic in COPD patients. Respir Res 10 20. 
Li L, Chen SH, Yu CH, Li YM & Wang SQ 2008 Identifica-
tion of hepatocellular-carcinoma-associated antigens and 
autoantibodies by serological proteome analysis combined 
with protein microarray. J Proteome Res 7 611-620. 
Liang QJ, Lu XF, Cheng XL, Luo S, He DC & Wang YC 
2004 [The active expression of CenpB, a constitutive protein 
in the centromeres of chromosomes, in breast cancer tis-
sues]. Yi.Chuan Xue Bao. 31 236-240. 
Liu H, Zhang J, Wang S, Pang Z, Wang Z, Zhou W & Wu 
M 2011a Screening of autoantibodies as potential bio-
markers for hepatocellular carcinoma by using T7 phase 
display system. Cancer Epidemiol doi:10.1016/
j.canep.2011.04.001. 
Liu X, Lv B & Guo W 2011b The size distribution of pro-
tein families within different types of folds. Biochem Bio-
phys Res Commun 406 218-222. 
Looi K, Megliorino R, Shi FD, Peng XX, Chen Y & Zhang 
JY 2006 Humoral immune response to p16, a cyclin-
dependent kinase inhibitor in human malignancies. Oncol-
Rep 16 1105-1110. 
Looi KS, Nakayasu ES, Diaz RA, Tan EM, Almeida IC & 
Zhang JY 2008 Using proteomic approach to identify tumor
-associated antigens as markers in hepatocellular carcinoma. 
J Proteome Res 7 4004-4012. 
Lu D, Kuhn E, Bristow RE, Giuntoli RL, Kjaer SK, Shih I 
& Roden RB 2011 Comparison of candidate serologic mark-
ers for type I and type II ovarian cancer. Gynecol Oncol 122 
560-566. 
Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Ca-
zals D, Hirsch A & Soussi T 1995 Serum p53 antibodies as 
early markers of lung cancer. Nat Med 1 701-702. 
Ludwig N, Keller A, Heisel S, Leidinger P, Klein V, Rhein-
heimer S, Andres CU, Stephan B, Steudel WI, Graf NM, 
Burgeth B, Weickert J, Lenhof HP & Meese E 2009 Im-
proving seroreactivity-based detection of glioma. Neoplasia 
11 1383-1389. 
Messmer BT, Nour-Omid TS, Ghia E, Sanchez AB & Kipps 
TJ 2011 Autoantibodies against p53 are associated with 
chromosome 17p deletions in chronic lymphocytic leuke-
mia. Leuk Res 35 965-967. 
Nakano M, Ohuchi Y, Hasegawa H, Kuroda T, Ito S & Ge-
jyo F 2000 Clinical significance of anticentromere antibod-
ies in patients with systemic lupus erythematosus. J Rheu-
matol 27 1403-1407. 
Nesterova MV, Johnson N, Cheadle C, Bates SE, Mani S, 
Stratakis CA, Khan IU, Gupta RK & Cho-Chung YS 2006 
Autoantibody cancer biomarker: extracellular protein kinase 
A. Cancer Res 66 8971-8974. 
Piura E & Piura B 2011 Autoantibodies to tailor-made pan-
els of tumor-associated antigens in breast carcinoma. J On-
col 2011 982425. 
Preininger C, Bodrossy L, Sauer U, Pichler R & Weilharter 
A 2004 ARChip epoxy and ARChip UV for covalent on-
chip immobilization of pmoA gene-specific oligonucleo-
tides. Anal Biochem 330 29-36. 
R Development Core Team 2005 R: A Language and Envi-
ronment for Statistical Computing. R Foundation for Statis-
tical Computing. 
Sanchez-Carbayo M 2006 Antibody arrays: technical con-
siderations and clinical applications in cancer. Clin Chem 52 
1651-1659. 
Schacherer F, Choi C, Gotze U, Krull M, Pistor S & Win-
gender E 2001 The TRANSPATH signal transduction data-
base: a knowledge base on signal transduction networks. 
Bioinformatics 17 1053-1057. 
Schmitt J, Heisel S, Keller A, Leidinger P, Ludwig N, Habel 
N, Furtwangler R, Nourkami-Tutdibi N, Wegert J, Grundy 
P, Gessler M, Graf N, Lenhof HP & Meese E 2011 Multi-
center study identified molecular blood-born protein signa-
tures for Wilms Tumor. Int J Cancer doi:10.1002/ijc.26419. 
Simon R & Lam A 2009 BRB-ArrayTools User Guide, ver-
127   Journal of Molecular Biochemistry, 2012 
sion 3.2. Biometric Research Branch, National Cancer Insti-
tute. http://linus.nci.nih.gov/brb. Biometric Research 
Branch, National Cancer Institute. http://linus.nci.nih.gov/
brb. 
Soussi T 2000 p53 Antibodies in the sera of patients with 
various types of cancer: a review. Cancer Res 60 1777-
1788. 
Stempfer R, Syed P, Vierlinger K, Pichler R, Meese E, Leid-
inger P, Ludwig N, Kriegner A, Nohammer C & Wein-
hausel A 2010 Tumour auto-antibody screening: perform-
ance of protein microarrays using SEREX derived antigens. 
BMC Cancer 10 627. 
Suzuki A, Iizuka A, Komiyama M, Takikawa M, Kume A, 
Tai S, Ohshita C, Kurusu A, Nakamura Y, Yamamoto A, 
Yamazaki N, Yoshikawa S, Kiyohara Y & Akiyama Y 2010 
Identification of melanoma antigens using a Serological 
Proteome Approach (SERPA). Cancer Genomics Pro-
teomics 7 17-23. 
The Gene Ontology Consortium 2000 Gene ontology: tool 
for the unification of biology. Nat Genet 25 25-29 
Tibshirani R, Hastie T, Narasimhan B & Chu G 2002 Diag-
nosis of multiple cancer types by shrunken centroids of gene 
expression. Proc Natl Acad Sci U.S.A 99 6567-6572. 
Tomaino B, Cappello P, Capello M, Fredolini C, Ponzetto 
A, Novarino A, Ciuffreda L, Bertetto O, De AC, Gaia E, 
Salacone P, Milella M, Nistico P, Alessio M, Chiarle R, 
Giuffrida MG, Giovarelli M & Novelli F 2007 Autoantibody 
signature in human ductal pancreatic adenocarcinoma. J 
Proteome Res 6 4025-4031. 
Trivers GE, De B, V, Cawley HL, Caron G, Harrington AM, 
Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, 
Miller RD & Harris CC 1996 Anti-p53 antibodies in sera 
from patients with chronic obstructive pulmonary disease 
can predate a diagnosis of cancer. Clin Cancer Res 2 1767-
1775. 
Zaytseva YY, Wang X, Southard RC, Wallis NK & Kilgore 
MW 2008 Down-regulation of PPARgamma1 suppresses 
cell growth and induces apoptosis in MCF-7 breast cancer 
cells. Mol Cancer 7 90. 
Zhang J, Wang K, Zhang J, Liu SS, Dai L & Zhang JY 2011 
Using proteomic approach to identify tumor-associated pro-
teins as biomarkers in human esophageal squamous cell 
carcinoma. J Proteome Res 10 2863-2872. 
Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK & 
Tan EM 2003 Enhancement of antibody detection in cancer 
using panel of recombinant tumor-associated antigens. Can-
cer Epidemiol Biomarkers Prev 12 136-143. 
Zhong L, Ge K, Zu JC, Zhao LH, Shen WK, Wang JF, 
Zhang XG, Gao X, Hu W, Yen Y & Kernstine KH 2008 
Autoantibodies as potential biomarkers for breast cancer. 
Breast Cancer Res 10 R40. 
Journal of Molecular Biochemistry, 2012   128 
